~~<i id='8872A594EC'><strike id='8872A594EC'><tt id='8872A594EC'><pre id='8872A594EC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：Wikipedia 2025-08-08 08:10:14 - browse：6472

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： The struggle to figure out which patients 'deserve' Wegovy

hotspot

entertainment

focus

explore

NIHgaveaprojecttostudyandfindtreatmentsforlongCovidmoremoneythisweek.AdobeWASHINGTON—TheBidenadminis

WSS

Assistant physicians can help address the primary care shortage

Doctors on social media are being harassed and cyberbullied

Here’s what’s in the FDA plan to include pregnant women in clinical trials

The struggle to figure out which patients 'deserve' Wegovy

David Liu startup to focus on CRISPR delivery

Medicare to pay more for cardiac rehab in hospital outpatient clinics

knowledge

hotspot

hotspot

The high cost of giving birth even with insurance

Why Eli Lilly’s earnings didn’t quite live up to the hype

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Jerome Adams on the need for new antivirals for Covid

Information blocking fines are now fair game in health care

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Amylyx, Aurinia, and IQVIA

As demand for Covid shots wanes, Moderna seeks its next success

Here’s what’s in the FDA plan to include pregnant women in clinical trials

entertainment

Eli Lilly CEO gives to Mike Pence presidential super PAC

People with substance use disorder deserve online privacy

How the messy conversation about Dolly changed bioethics

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Why the drug industry's warnings on the IRA's impact fall short

Websites selling Wegovy, Zepbound ingredients targeted by FDA

focus

focus

focus

explore